BJH - volume 14, issue 5, september 2023
J. Blokken PhD, PharmD
In 2022, both the World Health Organisation (WHO) and International Consensus Classification (ICC) have updated the classification of acute myeloid leukaemia (AML) in order to reflect recent advances in disease understanding. In terms of secondary AML, there are now new definitions of therapy-related AML and AML with myelodysplasia-related changes. Furthermore, it is becoming more and more clear that also older patients benefit from intensive chemotherapy, followed by haematopoietic stem cell transplantation. With regard to Vyxeos Liposomal, a multitude of real-world studies could confirm the safety and efficacy that was observed in the randomised, phase III Study 301.
Read moreBJH - volume 14, issue 5, september 2023
J. Blokken PhD, PharmD
EHA 2023 again featured a plethora of interesting oral abstracts and poster presentations in the field of acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). In this article, we will highlight some of the most promising data with regard to AML clinical studies, novel combinations in the treatment of AML and risk stratification. Furthermore, we will discuss some important clinical updates in the field of MDS.
(BELG J HEMATOL 2023;14(5):221–5)
Read moreBJH - volume 14, issue 5, september 2023
J. Blokken PhD, PharmD
The EHA 2023 congress was not only the opportunity to present updates on immune therapeutic treatments in acute lymphoblastic leukaemia (ALL), but also was also the occasion to present some clinical updates of important clinical studies in this setting. Below, we will discuss some of the key take-away messages from both sessions.
(BELG J HEMATOL 2023;14(5):226–9)
Read moreBJH - volume 14, issue 4, june 2023
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.
(BELG J HEMATOL 2023;14(4):192–5)
Read moreBJH - volume 14, issue 3, may 2023
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the Belgian Journal of Hematology (BJH), we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on haematology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjh.be) and we will make sure to include it in the journal scan section of the next BJH issue.
(BELG J HEMATOL 2023;14(3):145–8)
Read moreBJH - 2023, issue Special, february 2023
J. Blokken PhD, PharmD, T. Feys MBA, MSc
Bispecific antibodies (BsAbs) represent a promising new treatment modality for many patients. Several clinical trials with BsAbs have emerged over the past years, either evaluating these agents monotherapy or in combination with other drugs. BsAbs offer an off-the shelf alternative for CAR-T cell therapy and have already been used successfully as salvage therapy after CAR-T cell failure. First, Prof. Guillaume Cartron (CHU Montpellier, University of Montpellier) gave an update of the use of BsAbs in non-Hodgkin lymphoma. Thereafter, Prof. Nathalie Meuleman (Hôpital Erasme, ULB) shared her expertise and gave an overview on the use of bispecifics in multiple myeloma.
Read moreBJH - 2023, issue Special, february 2023
J. Blokken PhD, PharmD, T. Feys MBA, MSc
The journey a drug makes from the laboratory to the patient’s bedside is very long. After years of clinical research and development, a lengthy administrative procedure needs to be completed. It starts with the granting of a marketing authorisation by the EMA and is followed in Belgium by a reimbursement decision. In order to get a better view on how a drug gets reimbursed in Belgium, Diane Kleinermans (RIZIV-INAMI, President CRM/CTG, Brussels), Marjan Willaert (Policy Advisor – Market Access, Pharma.be, Brussels), and Hanne Wouters (Market Access Advisor, Pharma.be, Brussels) gave an overview on the evaluation and review by the commission for reimbursement of medicines (CRM).
Read moreTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.